GlassScriptPhysician profile
Zoe D Hartmann
NPI 1699546705
$1,502.19
in general payments reported to CMS, 2019-2025
24 companies · $618 in 2025
The $618 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $884 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $305.31 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $174.57 | 2024-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $144.08 | 2024-2025 | |
| Pfizer INC. | $116.65 | 2024-2025 | |
| Boston Scientific Corporation | $89.95 | 2024-2025 | Watchman Flx, Watchman |
| Edwards Lifesciences Corporation | $83.28 | 2024-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $72.06 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $65.12 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $58.07 | 2024 | Arcalyst |
| Novo Nordisk INC | $41.95 | 2024 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.43 | 2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $39.91 | 2024-2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $39.60 | 2024-2025 | Evkeeza |
| Impulse Dynamics (USA) INC. | $33.54 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $30.94 | 2024 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $23.64 | 2024 | |
| Cvrx, INC. | $23.39 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $22.56 | 2025 | Opsumit, Uptravi |
| Medtronic, INC. | $18.94 | 2025 | Symplicity G3 |
| Inspire Medical Systems, INC. | $18.08 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $15.61 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $15.60 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $15.54 | 2025 | |
| Abbott Laboratories | $13.37 | 2024 | Aveir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoe Hartmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.